Tyler Dylan-Hyde Insider Trading Transactions
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Tyler Dylan-Hyde.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Tyler Dylan-Hyde. Tyler Dylan-Hyde is Chief Legal Officer in CRISPR Therapeutics AG ($CRSP).
Latest Insider Trading Transactions of Tyler Dylan-Hyde
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Option Exercise | M | 12.57 | 19,890 | 250,017 | 5,237 | |
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Option Exercise | M | 12.57 | 1,110 | 13,953 | 36,663 | |
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 28.10 | 19,890 | 558,909 | 25,204 | 45.1 K to 25.2 K (-44.11 %) |
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Buy | M | 12.57 | 19,890 | 250,017 | 45,094 | 25.2 K to 45.1 K (+78.92 %) |
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 28.24 | 1,110 | 31,346 | 25,204 | 26.3 K to 25.2 K (-4.22 %) |
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Buy | M | 12.57 | 1,110 | 13,953 | 26,314 | 25.2 K to 26.3 K (+4.40 %) |
Jan 18 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 28.00 | 45,000 | 1,260,000 | 25,204 | 70.2 K to 25.2 K (-64.10 %) |
Jan 04 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Option Exercise | M | 12.57 | 1,510 | 18,981 | 25,157 | |
Jan 04 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Option Exercise | M | 12.57 | 6,490 | 81,579 | 37,773 | |
Jan 04 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 25.75 | 8,000 | 206,000 | 70,204 | 78.2 K to 70.2 K (-10.23 %) |
Jan 04 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Buy | M | 12.57 | 8,000 | 100,560 | 78,204 | 70.2 K to 78.2 K (+11.40 %) |
Jan 04 2018 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 20.55 | 30,000 | 616,500 | 70,204 | 100.2 K to 70.2 K (-29.94 %) |
Dec 27 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 20.55 | 15,000 | 308,250 | 115,204 | 130.2 K to 115.2 K (-11.52 %) |
Dec 19 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.90 | 15,000 | 283,496 | 130,204 | 145.2 K to 130.2 K (-10.33 %) |
Aug 08 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.60 | 1,313 | 24,422 | 153,204 | 154.5 K to 153.2 K (-0.85 %) |
Aug 08 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.56 | 13,210 | 245,209 | 154,517 | 167.7 K to 154.5 K (-7.88 %) |
Aug 08 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.55 | 477 | 8,848 | 167,727 | 168.2 K to 167.7 K (-0.28 %) |
Jun 19 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Option Exercise | A | 14.43 | 65,000 | 937,950 | 65,000 | |
May 03 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.61 | 1,852 | 30,753 | 168,204 | 170.1 K to 168.2 K (-1.09 %) |
Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.62 | 4,912 | 81,638 | 170,056 | 175 K to 170.1 K (-2.81 %) |
Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.84 | 13,527 | 227,799 | 174,968 | 188.5 K to 175 K (-7.18 %) |
Apr 28 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.76 | 3,200 | 53,641 | 180,495 | 183.7 K to 180.5 K (-1.74 %) |
Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.87 | 4,800 | 80,990 | 183,695 | 188.5 K to 183.7 K (-2.55 %) |
Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 16.44 | 3,522 | 57,897 | 188,495 | 192 K to 188.5 K (-1.83 %) |
Apr 25 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 17.02 | 3,010 | 51,222 | 192,017 | 195 K to 192 K (-1.54 %) |
Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 17.37 | 2,937 | 51,025 | 195,027 | 198 K to 195 K (-1.48 %) |
Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 18.58 | 2,310 | 42,916 | 197,964 | 200.3 K to 198 K (-1.15 %) |
Apr 21 2017 | CRSP | CRISPR Therapeutic ... | Dylan-Hyde Tyler | Chief Legal Officer | Sell | S | 17.49 | 4,930 | 86,249 | 200,274 | 205.2 K to 200.3 K (-2.40 %) |
Page: 1